District of Delaware Issues a Bellwether Decision on Bellwether Trials

Aug 4, 2017

Reading Time : 2 min

In Intel, Intel Corporation (“Intel”) filed for declaratory judgment of noninfringement and invalidity on nine patents owned by Future Link Systems, LLC (FLS). In response, FLS filed counterclaims for infringement against Intel on 15 patents. In the pleadings, “FLS contends that it is entitled to approximately $10 billion in reasonable royalties, while Intel counters that it was liable for only around $10 million, a disparity of about 1,000 times.” (emphasis is original).

Characterizing the case as an “oversized patent case,” Judge Stark considered two alternative strategies for narrowing the issues and promoting settlement. The first approach considered was an “unusual” “reverse bifurcat[ion]” of the case, where a trial would be conducted on only damages for a subset of six of the 15 patents, “solely to obtain a verdict on the parties’ competing damages theories, on the assumption that all asserted patents are valid and infringed by all accused products.” The second approach considered was a “well-worn . . . ‘bellwether’ trial on liability and damages relating to just three patents.” Ultimately, Judge Stark adopted the “bellwether” approach, reasoning that it would “giv[e] the parties a near-term opportunity to obtain certainty . . . as to the value of a substantial subset of their disputes,” especially given that FLS placed one-third of the total value ($2.9 billion) on the three representative patents.

Balancing the “totality of circumstances” in favor of the bellwether approach, the court maintained, “obtaining clarity on the value of one third (even a nonrepresentative one-third, if that is what it is) of the case is at least as likely to promote settlement as would an advisory damages verdict on the entirety of the case,” which is “all that could be accomplished by a reverse bifurcation.” The court further reasoned, “Should, in a subsequent trial, even a single [infringement or validity] assumption with respect to any patent fail, the damages-only verdict with respect to (at least) that patent would become a nullity.” Finally, the court recognized the potential for portions of the case to carry on “for many, many years to come,” but offered to be “receptive to reasonable suggestions as to how to manage this case most efficiently, in light of its overwhelming size and complexity.”

The parties are set to go to a bellwether jury trial in September of this year, the outcome of which should significantly influence at least one party’s disparate valuation of the case.

Intel Corporation v. Future Link Systems LLC, 1-14-cv-00377 (DED July 31, 2017, Order) (Stark, USDJ)

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.